NCT04629378View on ClinicalTrials.gov

Evaluating the EBA of Meropenem With Amoxicillin/Clavulanate and Pyrazinamide or Bedaquiline in Adults With PTB

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 17, 2020

Primary Completion Date

June 4, 2021

Study Completion Date

June 4, 2021

Conditions

Tuberculosis

Interventions

DRUG

Meropenem Injection

Meropenem IV 6 grams

DRUG

Amoxicillin Clavulanate

Amx/CA oral 1000/62.5mg 2 tablets

DRUG

Pyrazinamide

Pyrazinamide 20-30mg/kg

DRUG

Bedaquiline

Bedaquiline 400mg

DRUG

Rifafour

Rifafour (HRZE) Standard dose

Trial Locations (1)

7530

TASK Clinical Research Centre, Cape Town

All Listed Sponsors

lead

TASK Applied Science

OTHER

NCT04629378 - Evaluating the EBA of Meropenem With Amoxicillin/Clavulanate and Pyrazinamide or Bedaquiline in Adults With PTB | Biotech Hunter | Biotech Hunter